Skip to main content
. 2019 May 30;8(6):523. doi: 10.3390/cells8060523

Table 2.

Primary efficacy analysis: percentage of patients in remission at week 6 (ITT population).

IBD98-M 0.8 g/day (N = 17) IBD98-M 1.2 g/day (N = 16) Placebo (N = 18)
Remission at Week 6 n (%) 1 (5.9) 2 (12.5) 2 (11.1)
95% confidence interval 0.1, 28.7 1.6, 38.3 1.4, 34.7
p value versus placebo >0.999 >0.999

Abbreviations: ITT = intent-to-treat; UCDAI = Ulcerative Colitis Disease Activity Index.